Comparison
Abeta Amyloidosis Arctic Type C2751494 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between Abeta Amyloidosis Arctic Type and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
Abeta Amyloidosis Arctic Type C2751494
Hereditary amyloidosis from APP gene mutation causing amyloid buildup in brain blood vessels. Runs in families. Managed symptomatically.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
Abeta Amyloidosis Arctic Type C2751494
50-65
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
Abeta Amyloidosis Arctic Type C2751494
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
Abeta Amyloidosis Arctic Type C2751494
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
Abeta Amyloidosis Arctic Type C2751494
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
Abeta Amyloidosis Arctic Type C2751494
neurologic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
Abeta Amyloidosis Arctic Type C2751494
rare-disease
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
abeta-amyloidosis-arctic-type-C2751494 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abeta Amyloidosis Arctic Type C2751494 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Age at recognition | Typically recognized in adulthood, with supplied onset around 50–65 years. | Congenital and present from early life; developmental concerns may arise in childhood. | High |
| Main clinical pattern | Neurologic disease linked to amyloid in brain blood vessels; exact symptoms are not specified. | May include developmental delay, neurologic features, and possible kidney involvement. | Moderate |
| Genetic basis | Familial APP-related amyloidosis; not communicable. | Chromosome 17q12 deletion that may be new or inherited; not communicable. | High |
When to favor each condition
Choose Abeta Amyloidosis Arctic Type C2751494 when
Adult-onset familial neurologic disease
The supplied onset is 50–65 years and the stated mechanism is an APP mutation.
High
Suspected cerebral vascular amyloid disease
The description centers on amyloid buildup in brain blood vessels, not a congenital syndrome.
Moderate
Symptomatic neurologic management
Management is described as symptomatic; no disease-specific therapy is established here.
Moderate
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Congenital or early developmental presentation
Onset is from early life, unlike the stated adult onset of Arctic-type amyloidosis.
High
Developmental concerns with possible kidney involvement
The source specifically mentions developmental, neurologic, and potential kidney features.
Moderate
Need for long-term supportive monitoring
Management is described as regular monitoring and supportive therapies.
Moderate
How key tests differ
| Test | Abeta Amyloidosis Arctic Type C2751494 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Genetic testing | APP variant testing may support the named hereditary amyloidosis. | Chromosomal microarray or equivalent testing may detect a 17q12 deletion. | A positive result supports the corresponding condition but still requires clinical correlation. |
| Brain imaging | May assess cerebrovascular amyloid-related changes; expected findings are not specified. | Not the defining test; neurologic assessment is individualized. | Imaging does not replace genetic confirmation or establish either diagnosis alone. |
| Kidney evaluation | Kidney involvement is not described in the supplied source. | Renal function or imaging may be monitored because involvement is possible. | An abnormal kidney result is a finding, not by itself a diagnosis of 17q12 deletion. |
Prognosis comparison
Abeta Amyloidosis Arctic Type C2751494
- Outcome
- Severe chronic neurologic disease is described; survival and progression rates are not established.
- Factors
- Age at onset, neurologic burden, and the family-specific APP variant may influence course, but effects are unquantified.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- A moderate chronic congenital condition with variable developmental and possible kidney effects.
- Factors
- Confirmed deletion, developmental needs, and kidney findings may influence the course.
Time frame: Arctic type is adult-onset, while 17q12 deletion is lifelong from early life; exact timelines are unavailable.
Prognosis must be individualized. This source provides no mortality or treatment-response data.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic progression | A severe chronic neurologic course is described, without enumerated complications. Neurologic features may occur, with overall severity described as moderate and variable. Specific complication rates are not established and should not be assumed to match. |
| Developmental disability | Not suggested as the typical presentation given adult onset. Developmental delay may affect learning, communication, and independence. Supportive developmental therapy is relevant to the deletion syndrome. |
| Kidney complications | Not established from the supplied description. Possible kidney involvement warrants monitoring; exact risk is not given. Abnormal renal tests require clinician interpretation and are not diagnostic alone. |
Patient education highlights
- HighGenetic counseling
Both conditions are genetic and not contagious. Counseling can clarify testing, inheritance, and family implications.
- HighSymptom monitoring
Report new neurologic, developmental, or urinary symptoms promptly. No exact warning thresholds are established here.
- MediumCare planning
Arctic type is managed symptomatically; 17q12 deletion needs ongoing monitoring and supportive therapies.